Purpose of Review
Opioid overdoses have risen starkly over the last two decades in the USA and are now among the leading causes of overall mortality. This review summarizes the current literature on risk factors for overdose as well as public health solutions.
Although opioid overdose mortality is highest among men and non-Hispanic whites, the rate of death is rising more rapidly now among women and non-Hispanic blacks. Incarceration remains a significant risk factor for overdose death, especially in the first weeks upon reentry reflecting the absence of treatment in prisons and jails despite strong evidence for the benefits of pharmacotherapy integration into these settings. Pharmacotherapy with either methadone or buprenorphine greatly reduces the risk of overdose; however, treatment discontinuation leads to an increase risk of death.
Naloxone distribution both through co-prescribing and community-based opioid overdose prevention programs remains the fundament of the public health response. Both are effective and cost-effective in reducing overdose; however, uptake is hampered due to variance in state naloxone access and Good Samaritan laws. Supervised injection facilities are a promising innovation to address overdose, especially in communities with high overdose rates.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
O’Donnell JK, Gladden RM, Seth P. Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region—United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66(34):897–903.
Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016. MMWR Morb Mortal Wkly Rep. 2018;67(12):349–58.
HIV surveillance—United States, 1981-2008. MMWR Morb Mortal Wkly Rep. 2011;60(21):689–93.
Vietnam War U.S. military fatal casualty statistics. [cited 2018 June 2]; Available from: https://www.archives.gov/research/military/vietnam-war/casualty-statistics#date.
•• Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci U S A. 2015;112(49):15078–83. Demonstrated how the opioid crisis has shifted mortality for middle-aged non-Hispanic whites in the USA, primarily due to overdose.
Case A, Deaton A. Mortality and morbidity in the 21st century. Brook Pap Econ Act. 2017;2017:397–476.
Slavova S, O’Brien DB, Creppage K, Dao D, Fondario A, Haile E, et al. Drug overdose deaths: let’s get specific. Public Health Rep. 2015;130(4):339–42.
Ruhm CJ. Geographic variation in opioid and heroin involved drug poisoning mortality rates. Am J Prev Med. 2017;53(6):745–53.
Horon IL, Singal P, Fowler DR, Sharfstein JM. Standard death certificates versus enhanced surveillance to identify heroin overdose-related deaths. Am J Public Health. 2018;108(6):777–81.
• Brady JE, et al. Risk markers for fatal and non-fatal prescription drug overdose: a meta-analysis. Inj Epidemiol. 2017;4(1):24. A systematic review of 29 studies which identified substance use disorder, psychiatric disorders, white race, age and male sex as risk factors for overdose.
Schiavon S, Hodgin K, Sellers A, Word M, Galbraith JW, Dantzler J, et al. Medical, psychosocial, and treatment predictors of opioid overdose among high risk opioid users. Addict Behav. 2018. https://doi.org/10.1016/j.addbeh.2018.05.029.
Mitra G, Wood E, Nguyen P, Kerr T, DeBeck K. Drug use patterns predict risk of non-fatal overdose among street-involved youth in a Canadian setting. Drug Alcohol Depend. 2015;153:135–9.
Lake S, Hayashi K, Buxton J, Milloy MJ, Dong H, Wood E, et al. The effect of prescription opioid injection on the risk of non-fatal overdose among people who inject drugs. Drug Alcohol Depend. 2015;156:297–303.
Shah NG, Lathrop SL, Reichard RR, Landen MG. Unintentional drug overdose death trends in New Mexico, USA, 1990–2005: combinations of heroin, cocaine, prescription opioids and alcohol. Addiction. 2008;103(1):126–36.
Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990–98. Addiction. 2003;98(6):739–47.
Bohnert ASB, Walton MA, Cunningham RM, Ilgen MA, Barry K, Chermack ST, et al. Overdose and adverse drug event experiences among adult patients in the emergency department. Addict Behav. 2017. https://doi.org/10.1016/j.addbeh.2017.11.030.
Walton GR, et al. The impact of benzodiazepine use on mortality among polysubstance users in Vancouver, Canada. Public Health Rep. 2016;131(3):491–9.
Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy J, Ilgen MA, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. Jama. 2011;305(13):1315–21.
Caudarella A, Dong H, Milloy MJ, Kerr T, Wood E, Hayashi K. Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend. 2016;162:51–5.
Stoove MA, Dietze PM, Jolley D. Overdose deaths following previous non-fatal heroin overdose: record linkage of ambulance attendance and death registry data. Drug Alcohol Rev. 2009;28(4):347–52.
Frenk SM, Porter KS, Paulozzi LJ. Prescription opioid analgesic use among adults: United States, 1999–2012. NCHS Data Brief. 2015;(189):1–8. https://www.cdc.gov/nchs/data/databriefs/db189.pdf.
• Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–82. CDC report highlighting the sharp increase in fentanyl and other synthetic opioids in overdose deaths.
Liang Y, Goros MW, Turner BJ. Drug overdose: differing risk models for women and men among opioid users with non-cancer pain. Pain Med. 2016;17(12):2268–79.
•• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. Jama. 2016;315(15):1624–45. Opioid prescribing guidelines which include summary evidence of the lack of benefit of chronic opioid therapy for chronic pain.
U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR. 2017 December 11; Available from: https://www.fda.gov/drugs/drugsafety/ucm352085.htm.
Huang X, Keyes KM, Li G. Increasing prescription opioid and heroin overdose mortality in the United States, 1999–2014: an age-period-cohort analysis. Am J Public Health. 2018;108(1):131–6.
Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. Jama. 2008;299(1):70–8.
Singhal A, Tien YY, Hsia RY. Racial-ethnic disparities in opioid prescriptions at emergency department visits for conditions commonly associated with prescription drug abuse. PLoS One. 2016;11(8):e0159224.
Joynt M, Train MK, Robbins BW, Halterman JS, Caiola E, Fortuna RJ. The impact of neighborhood socioeconomic status and race on the prescribing of opioids in emergency departments throughout the United States. J Gen Intern Med. 2013;28(12):1604–10.
Groenewald CB, Rabbitts JA, Hansen E, Palermo TM. Racial differences in opioid prescribing for children in the United States. Pain. 2018:1. https://doi.org/10.1097/j.pain.0000000000001290.
Shiels MS, Freedman ND, Thomas D, Berrington de Gonzalez A. Trends in U.S. drug overdose deaths in non-Hispanic Black, Hispanic, and non-Hispanic White persons, 2000–2015. Ann Intern Med. 2018;168(6):453–5.
Hsu DJ, McCarthy EP, Stevens JP, Mukamal KJ. Hospitalizations, costs and outcomes associated with heroin and prescription opioid overdoses in the United States 2001–12. Addiction. 2017;112(9):1558–64.
Golembeski C, Fullilove R. Criminal (in)justice in the city and its associated health consequences. Am J Public Health. 2005;95(10):1701–6.
Nellis A. The color of justice: racial and ethnic disparity in state prisons. 2016; Available from: http://www.sentencingproject.org/wp-content/uploads/2016/06/The-Color-of-Justice-Racial-and-Ethnic-Disparity-in-State-Prisons.pdf.
Ojmarrh M. A meta-analysis of race and sentencing research: explaining the inconsistencies. J Quant Criminol. 2005;21(4):439–66.
Csete J, Kamarulzaman A, Kazatchkine M, Altice F, Balicki M, Buxton J, et al. Public health and international drug policy. Lancet. 2016;387(10026):1427–80.
MacDonald J, Arkes J, Nicosia N, Pacula RL. Decomposing racial disparities in prison and drug treatment commitments for criminal offenders in California. J Leg Stud. 2014;43(1):155–87.
Kanato M. Drug use and health among prison inmates. Curr Opin Psychiatry. 2008;21(3):252–4.
• Fazel S, Bains P, Doll H. Substance abuse and dependence in prisoners: a systematic review. Addiction. 2006;101(2):181–91. Systematic review of 14 studies detailing high rate of addiction among prisoners, specifically among female prisoners.
Rounds-Bryant JL, Baker L Jr. Substance dependence and level of treatment need among recently-incarcerated prisoners. Am J Drug Alcohol Abuse. 2007;33(4):557–61.
Belenko S, Hiller M, Hamilton L. Treating substance use disorders in the criminal justice system. Curr Psychiatry Rep. 2013;15(11):414.
Fiscella K, Pless N, Meldrum S, Fiscella P. Alcohol and opiate withdrawal in US jails. Am J Public Health. 2004;94(9):1522–4.
• Nunn A, et al. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1–2):83–8. Survey of pharmacotherapy in prisons revealed that many systems do not offer medication or treatment referrals upon release.
• Hedrich D, et al. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107(3):501–17. Systematic review of 21 studies detailing benefits of pharmacotherapy in prisons including, decrease in risky behaviors while incarcerated and possible decrease in overdose death upon release.
Stallwitz A, Stover H. The impact of substitution treatment in prisons—a literature review. Int J Drug Policy. 2007;18(6):464–74.
Leach D, Oliver P. Drug-related death following release from prison: a brief review of the literature with recommendations for practice. Curr Drug Abuse Rev. 2011;4(4):292–7.
Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600.
Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison—a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–65.
Krinsky CS, Lathrop SL, Brown P, Nolte KB. Drugs, detention, and death: a study of the mortality of recently released prisoners. Am J Forensic Med Pathol. 2009;30(1):6–9.
Kouyoumdjian FG, Kiefer L, Wobeser W, Gonzalez A, Hwang SW. Mortality over 12 years of follow-up in people admitted to provincial custody in Ontario: a retrospective cohort study. CMAJ Open. 2016;4(2):E153–61.
• Merrall EL, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545–54. Meta-analysis of 6 studies demonstrating increased risk of overdose death in first month following release.
Forsyth SJ, Carroll M, Lennox N, Kinner SA. Incidence and risk factors for mortality after release from prison in Australia: a prospective cohort study. Addiction. 2018;113(5):937–45.
Bird SM, Hutchinson SJ. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996–99. Addiction. 2003;98(2):185–90.
Farrell M, Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction. 2008;103(2):251–5.
Bukten A, Stavseth MR, Skurtveit S, Tverdal A, Strang J, Clausen T. High risk of overdose death following release from prison: variations in mortality during a 15-year observation period. Addiction. 2017;112(8):1432–9.
Binswanger IA, Nowels C, Corsi KF, Glanz J, Long J, Booth RE, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7:3.
Farahmand P, Modesto-Lowe V, Chaplin MM. Prescribing opioid replacement therapy in U.S. correctional settings. J Am Acad Psychiatry Law. 2017;45(4):472–7.
Wakeman SE. Why it’s inappropriate not to treat incarcerated patients with opioid agonist therapy. AMA J Ethics. 2017;19(9):922–30.
Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract. 2015;10:2.
Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015;386(9991):350–9.
Degenhardt L, Larney S, Kimber J, Gisev N, Farrell M, Dobbins T, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014;109(8):1306–17.
Marsden J, Stillwell G, Jones H, Cooper A, Eastwood B, Farrell M, et al. Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England. Addiction. 2017;112(8):1408–18.
•• Sordo L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. Bmj. 2017;357:j1550. Meta-analysis quantifying the benefit of pharmacotherapy for the prevention of overdose among individuals with opioid use disorder.
Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009;105(1–2):9–15.
Bell JR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009;104(1–2):73–7.
Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1–3):151–7.
Clausen T, Waal H, Thoresen M, Gossop M. Mortality among opiate users: opioid maintenance therapy, age and causes of death. Addiction. 2009;104(8):1356–62.
Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O’Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103(3):462–8.
• Mattick RP, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):Cd002207. https://doi.org/10.1002/14651858.CD002207.Cochrane review demonstrating equivalence of both buprenorphine and methadone in suppressing illicit opioid use; methadone is superior in treatment retention.
Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abus Treat. 2015;52:48–57.
Bogdanowicz KM, Stewart R, Chang CK, Shetty H, Khondoker M, Day E, et al. Excess overdose mortality immediately following transfer of patients and their care as well as after cessation of opioid substitution therapy. Addiction. 2018;113(5):946–51.
Miller M, Barber CW, Leatherman S, Fonda J, Hermos JA, Cho K, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med. 2015;175(4):608–15.
Manchikanti L, Kaye AM, Knezevic NN, McAnally H, Slavin K, Trescot AM, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician. 2017;20(2s):S3–s92.
Behar E, Rowe C, Santos GM, Coffa D, Turner C, Santos NC, et al. Acceptability of naloxone co-prescription among primary care providers treating patients on long-term opioid therapy for pain. J Gen Intern Med. 2017;32(3):291–5.
Takeda MY, Katzman JG, Dole E, Bennett MH, Alchbli A, Duhigg D, et al. Co-prescription of naloxone as a universal precautions model for patients on chronic opioid therapy—observational study. Subst Abus. 2016;37(4):591–6.
Mueller SR, Koester S, Glanz JM, Gardner EM, Binswanger IA. Attitudes toward naloxone prescribing in clinical settings: a qualitative study of patients prescribed high dose opioids for chronic non-cancer pain. J Gen Intern Med. 2017;32(3):277–83.
Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146–55.
Alcorn T. America embraces treatment for opioid drug overdose. Lancet. 2014;383(9933):1957–8.
Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153–63.
Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abus. 2015;36(2):240–53.
Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WCN. Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the United Kingdom. Value Health. 2018;21(4):407–15.
Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158(1):1–9.
Lambdin BH, Davis CS, Wheeler E, Tueller S, Kral AH. Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States. Drug Alcohol Depend. 2018;188:370–6.
McClellan C, Lambdin BH, Ali MM, Mutter R, Davis CS, Wheeler E, et al. Opioid-overdose laws association with opioid use and overdose mortality. Addict Behav. 2018. https://doi.org/10.1016/j.addbeh.2018.03.014
Winograd RP, Davis CS, Niculete M, Oliva E, Martielli RP. Medical providers’ knowledge and concerns about opioid overdose education and take-home naloxone rescue kits within Veterans Affairs health care medical treatment settings. Subst Abus. 2017;38(2):135–40.
Pauly JB, Vartan CM, Brooks AT. Implementation and evaluation of an opioid overdose education and naloxone distribution (OEND) program at a Veterans Affairs Medical Center. Subst Abus. 2018:1–17. https://doi.org/10.1080/08897077.2018.1449174.
Bixler D, Corby-Lee G, Proescholdbell S, Ramirez T, Kilkenny ME, LaRocco M, et al. Access to Syringe Services Programs—Kentucky, North Carolina, and West Virginia, 2013–2017. MMWR Morb Mortal Wkly Rep. 2018;67(18):529–32.
McGowan CR, Harris M, Platt L, Hope V, Rhodes T. Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: do we know enough to promote it? Int J Drug Policy. 2018;58:31–6.
Kerr T, Mitra S, Kennedy MC, McNeil R. Supervised injection facilities in Canada: past, present, and future. Harm Reduct J. 2017;14(1):28.
Gaeta JM, Racine M. New strategies are needed to stop overdose fatalities: the case for supervised injection facilities. Ann Intern Med. 2018. https://doi.org/10.7326/M18-0258.
•• Marshall BD, et al. Reduction in overdose mortality after the opening of North America’s first medically supervised safer injecting facility: a retrospective population-based study. Lancet. 2011;377(9775):1429–37. Demonstrates local reduction in overdose death following the establishment of a supervised injection facility.
Davidson PJ, Lopez AM, Kral AH. Using drugs in un/safe spaces: impact of perceived illegality on an underground supervised injecting facility in the United States. Int J Drug Policy. 2018;53:37–44.
Harris RE, Richardson J, Frasso R, Anderson ED. Perceptions about supervised injection facilities among people who inject drugs in Philadelphia. Int J Drug Policy. 2018;52:56–61.
Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Aff (Millwood). 2017;36(5):945–51.
Bradford AC, Bradford WD. Medical marijuana laws reduce prescription medication use in Medicare part D. Health Aff (Millwood). 2016;35(7):1230–6.
Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, et al. Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis. Neuropsychopharmacology. 2017;42(9):1752–65.
Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med. 2014;174(10):1668–73.
Powell D, Pacula RL, Jacobson M. Do medical marijuana laws reduce addictions and deaths related to pain killers? J Health Econ. 2018;58:29–42.
Phillips E, Gazmararian J. Implications of prescription drug monitoring and medical cannabis legislation on opioid overdose mortality. J Opioid Manag. 2017;13(4):229–39.
Darke S, Farrell M. Would legalizing illicit opioids reduce overdose fatalities? Implications from a natural experiment. Addiction. 2014;109(8):1237–42.
Conflict of Interest
Thokozeni Lipato declares that he has no conflict of interest. Mishka Terplan declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
This article is part of the Topical Collection on Substance Use Disorders
About this article
Cite this article
Lipato, T., Terplan, M. Risk Factors for Opioid Overdose. Curr Treat Options Psych 5, 323–333 (2018). https://doi.org/10.1007/s40501-018-0153-1
- Risk factors